Controlling Stake Sold for $400K, Co-CEOs Resign, Company Pivots to Oil & Gas
BFNH has more than doubled off its 52-week low of $0.163 on elevated volume (16× avg).
Summary
BIOFORCE NANOSCIENCES HOLDINGS, INC. announced a change of control with 79.65% of shares sold for $400,000, followed by the resignation of its Co-Chief Executive Officers and Vice-President, and a strategic pivot from the vitamin supplement industry to the oil and gas industry.
Key Events · Corporate Governance and Compliance · BFNH
-
Change of Control
On April 15, 2026, Merle Ferguson, a Director, sold his controlling interest of 26,700,000 shares (79.65% of outstanding common stock) to Nexus Capital Investments, Inc. for $400,000. This formalizes the change of control previously hinted at in the May 19, 2026 10-Q filing.
-
Executive Resignations
On June 17, 2026, Co-Chief Executive Officers Steven Gagnon and John LaViolette, along with Vice-President Sasha Shapiro, resigned from their positions.
-
Interim Leadership & New Director
Richard Kaiser, already the Chief Financial Officer, Secretary, and Director, was appointed interim Chief Executive Officer on June 17, 2026. Scott Mager was appointed as a new Director effective June 15, 2026.
-
Strategic Business Pivot
The company is changing its business operations from the vitamin supplement industry to the oil and gas industry, with management actively evaluating new opportunities.
Analysis · BFNH · Industrial Applications And Services
This filing details a complete overhaul of the company's ownership, leadership, and business strategy. The sale of a controlling stake (79.65%) for a mere $400,000, coupled with the departure of multiple top executives and a speculative pivot to the oil and gas industry, signals extreme distress and a high-risk, uncertain future for a company already reporting zero revenue and a going concern warning.
At the time of this filing, BFNH was trading at $1.78 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $59.7M. The 52-week trading range was $0.16 to $2.07. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.